CEVA Animal Health has added to its veterinary pharmaceutical portfolio with the introduction of anti-inflammatory Meloxidyl, which has the advantage of administration via a single injection when used in combination with suitable anti-infectives.
CEVA Animal Health has introduced the anti-inflammatory Meloxidyl to its veterinary pharmaceutical portfolio.
According to the company, Meloxidyl is a targeted, meloxicam-based solution enabling the management of respiratory disease, mastitis and diarrhoea in cattle and non-infectious locomotor disorders and puerperal septicaemia and toxaemia in pigs.
It has the advantage of administration via a single injection, when used in combination with suitable anti-infectives.
Meloxidyl’s one shot protocol means it’s quick and economical to use. It allows control of inflammation and endotoxins and reduces somatic cell count, recovery time and risk of culling after clinical mastitis. It also reduces the economical impact of respiratory signs in comparison with flunixin-based products and reduces the major clinical signs caused by toxins in cases of neonatal diarrhoea.
Meloxidyl can be used in combination with the company’s range of anti-infectives, which includes Marbokem, Cevaxel and Florkem.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the CEVA website.